<DOC>
	<DOCNO>NCT01773837</DOCNO>
	<brief_summary>Fatigue prevalent symptom advance cancer patient , interfere functional capacity , social relation , wellbeing , quality life . Methylphenidate central nervous system stimulant traditionally used cancer patient manage depression , opioid‐induced sedation , hypoactive delirium due multiorgan failure , cognitive disorder associate brain tumor . Although evidence prospective study efficacy drug cancer‐related fatigue , one randomise clinical trial give non-conclusive result . In order define real efficacy methylphenidate setting , investigator design new clinical trial compare methylphenidate placebo cancer‐related fatigue , assess verbal numeric scale ( VNS ) include Edmonton Symptom Assessment System ( ESAS ) subscale fatigue Functional Assessment Cancer Therapy ( FACT‐F ) . The investigator include 122 advanced cancer patient fatigue ≥ 5/10 ( VNS , 0 10 ) hemoglobin ≥ 9 g/dl . Patients randomized methylphenidate placebo . Doses adapt response within range 10 mg morning time 5 noon , 25 mg/day . Assessment response perform day 3 day 6 ESAS FACT‐F . Drug‐induced adverse event check . The VNS fatigue day 6 consider primary endpoint .</brief_summary>
	<brief_title>Clinical Trial Evaluate Short-term Efficacy Palliative Methylphenidate Asthenia Advanced Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthenia</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Advanced cancer ; include metastatic , locally advance relapse amenable curative treatment . Mini.mental status examination result within normal limit . Informed consent . Estimated life expectancy least one month . Hemoglobin &gt; = 9 g/dl . Asthenia &gt; = 5 ( 010 ; numeric verbal scale ) . History psychosis . Structured suicidal ideation . Severe anxiety . Severe renal , hepatic cardiac ( arrythmia , hypertension , ischemic heart disease ) failure . Simultaneous treatment drug may interact methylphenidate : coumarinics , anticonvulsivants ( phenobarbital , phenitoin , primidone ) , phenylbutazone , inhibitor monoamineoxidase , guanethidine . History glaucoma . Hyperthyroidism . History hypersensibility methylphenidate . Clinical suspicion : infection , hypercalcemia , hypothyroidism renal failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>asthenia</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>randomize control trial</keyword>
</DOC>